Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study

Abstract

Objective

The aim of this study was to evaluate the effect of hydroxychloroquine (HCQ) on fetal preterm delivery and intrauterine growth restriction (IUGR) in a cohort of pregnant women with systemic lupus erythematosus (SLE).

Methods

Over an 11-year period (January 1, 2001 to December 31, 2011), all women with SLE and admitted to deliver after 22 weeks of gestation to Bordeaux University Hospital (France), were retrospectively enrolled in the present study. The population was then split into two groups based on the treatment they received: HCQ exposed (HCQ+) versus HCQ non-exposed (HCQ−) group.

Results

118 pregnancies were included, 41 in the HCQ+ group and 77 in the HCQ− group. The rate of adverse fetal outcome was significantly lower in the HCQ+ group (p = 0.001), particularly in terms of preterm delivery, 15.8 % versus 44.2 % (p = 0.006), and IUGR, 10.5 % versus 28.6 % (p = 0.03). No adverse outcomes were reported in the HCQ+ group.

Conclusion

HCQ reduces neonatal morbidity in women with SLE by significantly decreasing the rate of prematurity and intrauterine growth restriction.

Keywords

Systemic lupus erythematosus pregnancy hydroxychloroquine prematurity intrauterine growth restriction

Get full access to this article

View all access options for this article.

References

Stojan

Baer

. Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol 2012; 8: 439–453.

Vinet

Labrecque

Pineau

. A population-based assessment of live births in women with systemic lupus erythematosus. Ann Rheum Dis 2012; 71: 557–559.

Barnabe

Faris

Quan

. Canadian pregnancy outcomes in rheumatoid arthritis and systemic lupus erythematosus. Int J Rheumatol 2011; 2011: 345727–345727.

Jung

Bobba

. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 863–868.

Zero-Time Assessment. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991; 324: 150–154.

Tsakonas

Joseph

Esdaile

. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 80–85.

Alarcón

McGwin

Bertoli

. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168–1172.

McChesney

. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 1983; 75(1): 11–18.

Parke

. Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 1988; 15: 607–610.

10.

Parke

West

. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996; 23: 1715–1718.

11.

Ruiz-Irastorza

Ramos-Casals

Brito-Zeron

Khamashta

. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20–28.

12.

Sperber

Hom

Chao

Shapiro

Ash

. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol 2009; 7: 9–9.

13.

Levy

Vilela

Cataldo

. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10: 401–404.

14.

Clowse

MEB

Magder

Witter

Petri

. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54: 3640–3647.

15.

Costedoat-Chalumeau

Amoura

Duhaut

. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48: 3207–3211.

16.

Costedoat-Chalumeau

Amoura

Huong

DLT

Lechat

Piette

J-C

. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 2005; 4: 111–115.

17.

Buchanan

Toubi

Khamashta

Lima

Kerslake

Hughes

. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996; 55: 486–488.

18.

Parke

. Antimalarial drugs and pregnancy. Am J Med 1988; 85(4): 30–33.

19.

Motta

Tincani

Faden

Zinzini

Chirico

. Antimalarial agents in pregnancy. Lancet 2002; 359: 524–525.

20.

Klinger

Morad

Westall

. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001; 358: 813–814.

21.

Barsalou

Jaeggi

Tian

Hamilton

Laskin

Silverman

. A149: does prenatal exposure to antimalarial decrease the risk of neonatal lupus: a Bayesian perspective. Arthritis Rheumatol 2014; 66(Suppl 3): S193–S193.

22.

Izmirly

Costedoat-Chalumeau

Pisoni

. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126(1): 76–82.

23.

Proceedings and abstracts of the 4th International Conference on Sex Hormones, Pregnancy and the Rheumatic Disease, September 20–22, 2004, Stresa, Italy. Lupus 2004; 13: 625–763.

24.

Al-Herz

Schulzer

Esdaile

. Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol 2002; 29: 700–706.

25.

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

26.

Bombardier

Gladman

Urowitz

Caron

Chang

. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

27.

Miyakis

Lockshin

Atsumi

. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

28.

Meyer

. Making pregnancy safer for patients with lupus. Joint Bone Spine 2004; 71: 178–182.

29.

Mamelle

Munoz

Grandjean

. Fetal growth from the AUDIPOG study. I. Establishment of reference curves. J Gynecol Obstet Biol Reprod (Paris) 1996; 25: 61–70.

30.

Mamelle

Munoz

Martin

Laumon

Grandjean

. Fetal growth from the AUDIPOG study. II. Application for the diagnosis of intrauterine growth retardation. J Gynecol Obstet Biol Reprod (Paris) 1996; 25: 71–77.

31.

Gladman

Goldsmith

Urowitz

. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994; 21: 1468–1471.

32.

Le Guern

Pannier

Goffinet

. Systemic lupus erythematosus and pregnancy. La Presse Médicale 2008; 37: 1627–1635.

33.

D’Cruz

Khamashta

Hughes

GRV

. Systemic lupus erythematosus. Lancet 2007; 369: 587–596.

34.

Lê Thi Huong

Wechsler

Piette

Blétry

Godeau

. French register of lupus in pregnancy: the evaluation. Groupe d’étude sur la grossesse lupique. Rev Med Interne 1994; 15: 305–317.

35.

Clark

Spitzer

Nadler

Laskin

. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003; 30: 2127–2132.

36.

Lima

Buchanan

Khamashta

Kerslake

Hughes

. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum 1995; 25: 184–192.

37.

Yasmeen

Wilkins

Field

Sheikh

Gilbert

. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 2001; 10: 91–96.

38.

Petri

Howard

Repke

Goldman

. The Hopkins Lupus Pregnancy Center: 1987–1991 update. Am J Reprod Immunol 1992; 28: 188–191.

39.

INSERM. French national perinatal survey. INSERM, 2010.

40.

Gouyon

J-B

Iacobelli

Ferdynus

Bonsante

. Neonatal problems of late and moderate preterm infants. Semin Fetal Neonatal Med 2012; 17: 146–152.

41.

Melamed

Klinger

Tenenbaum-Gavish

. Short-term neonatal outcome in low-risk, spontaneous, singleton, late preterm deliveries. Obstet Gynecol 2009; 114(2 Pt 1): 253–260.

42.

Hallowell

Spatz

. The relationship of brain development and breastfeeding in the late-preterm infant. J Pediatr Nurs 2012; 27: 154–162.

43.

Morse

Zheng

Tang

Roth

. Early school-age outcomes of late preterm infants. Pediatrics 2009; 123: e622–e629.

44.

Fox

. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996; 5(Suppl 1): S4–S10.

45.

Kuznik

Bencina

Svajger

Jeras

Rozman

Jerala

. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794–4804.

46.

Petri

. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 5(Suppl 1): S16–S22.

47.

Resnik

. Intrauterine growth restriction. Obstet Gynecol 2002; 99: 490–496.

48.

Ostensen

Clowse

. Pathogenesis of pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol 2013; 25: 591–596.

49.

López-Farfán

Martínez-Marín

Van Der Heyden-Pardo

. Uterine artery score in patients with systemic lupus erythematous as a predictor of intrauterine growth restriction. Ginecol Obstet Mex 2011; 79: 137–142.